Pyrazoline CB1 Antagonists for Peripheral Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-obesity medications are ineffective in maintaining weight loss over time and often come with undesirable and dangerous side effects due to their indirect mechanisms of action and brain penetration, which leads to CNS-related adverse effects.
Innovation Solution
Development of pyrazoline compounds that act as selective CB1 receptor antagonists/inverse agonists with limited or no CNS adverse effects by preferentially targeting peripheral tissues while sparing brain CB1 receptors, thereby reducing CNS exposure and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CNS appetite suppressants are used to treat obesity, then weight loss is achieved through activation of satiety center, but CNS-related adverse effects occur due to brain penetration
Solution Approach 1:
The patent segments the CB1 receptor distribution into central (brain) and peripheral (adipose tissue, liver, muscle, pancreas, gastrointestinal tract) components. By designing compounds with selective peripheral penetration, the invention targets only the peripheral segment of the endocannabinoid system, achieving weight loss through peripheral mechanisms while avoiding central nervous system exposure and associated adverse effects.
Solution Approach 2:
The patent applies local quality by creating compounds with differential tissue distribution properties. The pyrazoline compounds are designed to concentrate in peripheral tissues (adipose tissue, liver, muscle, pancreas, gastrointestinal tract) where CB1 receptors mediate metabolic functions, while maintaining low concentration in the brain. This localized action allows therapeutic effect in target tissues without CNS-related side effects.
2Reliability
If current anti-obesity medications are used, then initial weight loss is achieved, but weight is not maintained after one or two years
Solution Approach 1:
The patent establishes continuity of useful action by targeting peripheral CB1 receptors in metabolic tissues (adipose tissue, liver, muscle, pancreas, gastrointestinal tract) that continuously regulate energy metabolism. Unlike CNS appetite suppressants that only affect food intake temporarily, the pyrazoline compounds continuously modulate peripheral metabolic processes including lipid metabolism, glucose homeostasis, and energy expenditure, leading to sustained weight loss maintenance over time.
Solution Approach 2:
The patent uses peripheral CB1 receptors as intermediaries to mediate long-term metabolic regulation. The pyrazoline compounds act on CB1 receptors in adipose tissue, liver, muscle, pancreas, and gastrointestinal tract, which serve as intermediaries between the drug and metabolic processes. This intermediary mechanism provides continuous metabolic modulation rather than transient appetite suppression, enabling sustained weight loss maintenance.
3Reliability
If CB1 receptor antagonists are used to block hunger center, then eating behavior is reduced, but undesirable side effects complicate treatment
Solution Approach 1:
The patent extracts the harmful CNS-related side effects from the therapeutic mechanism by removing the central action component from CB1 receptor antagonism. The pyrazoline compounds are designed to selectively target peripheral CB1 receptors while excluding the brain, thereby extracting only the beneficial metabolic effects (weight loss, improved cardiometabolic parameters) without the harmful CNS-related adverse effects (psychiatric and neurological side effects) associated with central CB1 receptor blockade.
Data Source
AI summary
The present invention provides novel pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.